Jean‐Luc Teillaud

7.1k total citations · 2 hit papers
164 papers, 5.7k citations indexed

About

Jean‐Luc Teillaud is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Molecular Biology. According to data from OpenAlex, Jean‐Luc Teillaud has authored 164 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Radiology, Nuclear Medicine and Imaging, 80 papers in Immunology and 73 papers in Molecular Biology. Recurrent topics in Jean‐Luc Teillaud's work include Monoclonal and Polyclonal Antibodies Research (99 papers), Glycosylation and Glycoproteins Research (55 papers) and T-cell and B-cell Immunology (37 papers). Jean‐Luc Teillaud is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (99 papers), Glycosylation and Glycoproteins Research (55 papers) and T-cell and B-cell Immunology (37 papers). Jean‐Luc Teillaud collaborates with scholars based in France, United States and United Kingdom. Jean‐Luc Teillaud's co-authors include Wolf H. Fridman, Catherine Sautès‐Fridman, Riad Abès, Marie‐Caroline Dieu‐Nosjean, Sebastián Amigorena, Janine Moncuit, Nadège Jamin, Paul Dumas, Sophie Sibéril and Charles‐Antoine Dutertre and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Jean‐Luc Teillaud

158 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer

2014 598 citations Jean‐Luc Teillaud, Wolf H. Fridman et al. profile →
Tertiary lymphoid structures in anticancer immunity

2024 80 citations Jean‐Luc Teillaud, Marie‐Caroline Dieu‐Nosjean et al. Nature reviews. Cancer profile →

Peers

Countries citing papers authored by Jean‐Luc Teillaud

Since Specialization

Citations

This map shows the geographic impact of Jean‐Luc Teillaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Luc Teillaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Luc Teillaud more than expected).

Fields of papers citing papers by Jean‐Luc Teillaud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Luc Teillaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Luc Teillaud. The network helps show where Jean‐Luc Teillaud may publish in the future.

Co-authorship network of co-authors of Jean‐Luc Teillaud

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Luc Teillaud. A scholar is included among the top collaborators of Jean‐Luc Teillaud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Luc Teillaud. Jean‐Luc Teillaud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The prognostic significance of tertiary lymphoid structures in oral squamous cell carcinomas: a systematic review 2025 ·Frontiers in Oral Health ·(unknown), Jean‐Luc Teillaud, Marie‐Caroline Dieu‐Nosjean, Géraldine Lescaille, Juliette Rochefort	1
2	Tertiary lymphoid structures in anticancer immunity breakdown → 2024 ·Nature reviews. Cancer ·Jean‐Luc Teillaud, (unknown), (unknown), (unknown), Marie‐Caroline Dieu‐Nosjean	80
3	SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma 2022 ·Blood ·Sahar Kassem, (unknown), Nizar El-Murr, Nadège Carrié, (unknown), Alain Fournier, (unknown), Céline Nicolazzi, Marine Cuisinier, Isabelle Arnould, Sukhvinder Sidhu, Jill Corre, Hervé Avet‐Loiseau, Jean‐Luc Teillaud, Helgi van de Velde, Dmitri Wiederschain, Marielle Chiron, Ludovic Martinet, Angéla Virone-Oddos	17
4	Single-Domain Antibody–Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells 2013 ·Molecular Cancer Therapeutics ·(unknown), Amélie Cornillon, (unknown), Martine Chartier, Ghislaine Béhar, Charlotte Boix, Brigitte Kerfélec, Bruno Robert, André Pèlegrin, Patrick Chames, Jean‐Luc Teillaud, Daniel Baty	58
5	Human Macrophages and Dendritic Cells Can Equally Present MART-1 Antigen to CD8+ T Cells after Phagocytosis of Gamma-Irradiated Melanoma Cells 2012 ·PLoS ONE ·María Marcela Barrio, Riad Abès, Marina Colombo, (unknown), Charlotte Boix, (unknown), Emmanuelle Gélizé, (unknown), José Mordoh, Jean‐Luc Teillaud	43
6	A Differential Concentration-Dependent Effect of IVIg on Neutrophil Functions: Relevance for Anti-Microbial and Anti-Inflammatory Mechanisms 2011 ·PLoS ONE ·Sarah Casulli, Selma Topçu, (unknown), Stephan von Gunten, Hans‐Uwe Simon, Jean‐Luc Teillaud, Jagadeesh Bayry, Srini V. Kaveri, Carole Elbim	37
7	Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response 2010 ·Blood ·Riad Abès, Emmanuelle Gélizé, Wolf H. Fridman, Jean‐Luc Teillaud	155
8	Poster Session 2008 ·Human Antibodies ·Christophe de Romeuf, Grégory Dupont, (unknown), Charles‐Antoine Dutertre, Magali Le Garff‐Tavernier, Nathalie Fournier, (unknown), Jean‐Luc Teillaud, Dominique Bourel, (unknown), Rohit Kumar Singh, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
9	Activation of Human Peripheral IgM+ B Cells Is Transiently Inhibited by BCR-Independent Aggregation of FcγRIIB 2008 ·The Journal of Immunology ·Emilie Fournier, Sophie Sibéril, Anne Costes, Audrey Varin, Wolf H. Fridman, Jean‐Luc Teillaud, Catherine Sautès‐Fridman	13
10	Isolation and characterization of anti-Fc RIII (CD16) llama single-domain antibodies that activate natural killer cells 2007 ·Protein Engineering Design and Selection ·Ghislaine Béhar, Sophie Sibéril, (unknown), Patrick Chames, Martine Pugnière, Charlotte Boix, Catherine Sautès‐Fridman, Jean‐Luc Teillaud, Daniel Baty	72
11	Novel Ganglioside Antigen Identified by B Cells in Human Medullary Breast Carcinomas: The Proof of Principle Concerning the Tumor-Infiltrating B Lymphocytes 2005 ·The Journal of Immunology ·Beatrix Kotlán, (unknown), Jean‐Luc Teillaud, Wolf H. Fridman, József Tóth, (unknown), Mark C. Glassy	66
12	PURIFICATION OF SOLUBLE RECOMBINANT HUMAN FcγRII (CD32) 2001 ·Preparative Biochemistry & Biotechnology ·Nadège Gruel, Julius Chapiro, Wolf H. Fridman, Jean‐Luc Teillaud	4
13	Differential Modulation of Stimulatory and Inhibitory Fcγ Receptors on Human Monocytes by Th1 and Th2 Cytokines 2001 ·The Journal of Immunology ·Luminita Pricop, Patricia Redecha, Jean‐Luc Teillaud, Jürgen Frey, Wolf H. Fridman, Catherine Sautès‐Fridman, Jane E. Salmon	191
14	Immunociblage des tumeurs : situation et perspectives en 2000 2000 ·Bulletin du Cancer ·André Pèlegrin, Françoise Xavier, Jacques Barbet, Jacques Bartholeyns, Daniel Baty, Franz Buchegger, Jean‐François Chatal, (unknown), (unknown), Anne Gruaz‐Guyon, (unknown), Lee Leserman, Jean‐Pierre Mach, Bruno Robert, (unknown), Jean‐Luc Teillaud, (unknown)	1
15	Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments 1999 ·Oncogene ·Claude Caron de Fromentel, Nadège Gruel, Corinne Venot, Laurent Debüssche, Emmanuel Conseiller, Christine Dureuil, Jean‐Luc Teillaud, Bruno Tocqué, Laurent Bracco	67
16	Generation and Characterization of a Mouse Single-Chain Antibody Fragment Specific for Disialoganglioside (G _D2 ) 1997 ·Hybridoma ·Sandrine Moutel, Stéphane Birklé, Valérie Laurence, J Michon, Wolf H. Fridman, Jacques Aubry, Jean‐Luc Teillaud	10
17	Production and Characterization of Mouse Monoclonal Antibodies to Wild-Type and Oncogenic FLI-1 Proteins 1997 ·Hybridoma ·Thomas Melot, Nadège Gruel, (unknown), Nicolas Sévenet, Jean‐Luc Teillaud, Olivier Delattre	21
18	A New Set of Monoclonal Antibodies Against Human FcγRII (CD32) and FcγRIII (CD16): Characterization and Use in Various Assays 1997 ·Hybridoma ·Frédéric Vely, Nadège Gruel, Janine Moncuit, Olivier Cochet‐Escartin, Hélène Rouard, (unknown), Jérôme Galon, Catherine Sautès‐Fridman, Wolf H. Fridman, Jean‐Luc Teillaud	35
19	Facteur de nécrose tumorale alpha, interleukine 2, et IgG-BF III (CD 16). Evaluation des taux sériques dans les cancers gynécologiques. 1989 ·La Presse Médicale ·(unknown), Wolf H. Fridman, Jean‐Luc Teillaud	1
20	Fc receptors on cultured myeloma and hybridoma cells. 1985 ·The Journal of Immunology ·Jean‐Luc Teillaud, Betty Diamond, Roberta R. Pollock, (unknown), Matthew D. Scharff	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact